TruScreen Cervical Cancer Screening Centre Mexico City

NZX/ASX Announcement
3 August 2022
TruScreen-based cervical cancer screening centre opens in Mexico City
Key Highlights
• A TruScreen-based cervical cancer screening centre has opened in Cludad de Mexico (Mexico
City), operated by Mexpharm Medical Clinical.
• Mexpharm Medical Clinical is a leading healthcare provider in Mexico, specialising in
comprehensive medical care focussed on the needs of patients and clinicians.
• The centre will showcase TruScreen’s medical technology, act as a training centre, and provide
screening services to local People.
• The centre’s opening will further expand TruScreen’s footprint in a significant marketplace, with
the female population in Mexico now around 65 million.

TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company’) is pleased to announce the
establishment of a TruScreen-based cervical cancer screening centre in a new clinic in Cludad de Mexico
(Mexico City) operated by leading healthcare provider Mexpharm Medical Clinical.
The new clinic will use the TruScreen device for cervical cancer screening
Mexpharm Medical Clinical, a leader in healthcare care in Mexico, specialises in comprehensive medical care
focused on the needs of patients and clinicians. It provides state-of-the-art medical technologies and doctors
specialized in ophthalmology, endoscopy, gynecology-oncology, internal medicine, anesthesiology, and general
medicine. It delivers competitively priced, quality short-stay medical care with high level of professional medical
care. The agreement to operate the TruScreen-based cervical cancer screening centre in the Mexpharm clinic
was negotiated by the Company’s distributor in Mexico, Sunbird S.A. de C.V.

Figure 1: The waiting room in the Mexpharm clinic

Figure 2: The TruScreen cervical cancer screening operator in the Mexpharm clinic
The TruScreen package being supplied to Mexpharm
The centre will showcase TruScreen’s medical technology, act as a training centre, and provide screening
services to local people. It follows on TruScreen’s establishment of a service centre in Mexico during the 2022
financial year, obviating the need for medical devices to be returned to Australia for service and re-calibration.
TruScreen’s addressable market in Mexico is significant
Mexico has reported strong population growth for many years with a population of around 130 million. About
22 million residing in Mexico City. Within the total population number, more than 65 million are female, of whom
around half fall within the prime cervical cancer screening age of 25-64 years old.
1


Figure 3: Mexico’s population is around 130m (Data Source: The World Bank)

1
https://cdn.who.int/media/docs/default-source/country-profiles/cervical-cancer/cervical-cancer-mex-2021-country-
profile-en.pdf?sfvrsn=8a0b4124_38&download=true

60
70
80
90
100
110
120
130
140
1991199319951997199920012003200520072009201120132015201720192021
Million
Population of Mexico

Figure 4: Cervical cancer profile in Mexico (Source: World Health Organisation)
According to the hpvcentre.net, Mexico has a population of almost 50 million women ages 15 years and older
who are at risk of developing cervical cancer. Current estimates indicate that every year 9,439 women are
diagnosed with cervical cancer and 4,335 die from the disease. Cervical cancer ranks as the second most
frequent cancer among women in Mexico and the third most frequent cancer among women between 15 and
44 years of age.
2

TruScreen CEO Juliet Hull said: “We are thrilled to partner with highly respected healthcare group
Mexpharm
Medical Clinical. The TruScreen-based cervical cancer screening centre in their new clinic in Mexico City will
further build on our existing presence in the huge Mexican market. We look forward to using it to showcase our
unique medical technology and provide cervical cancer screening services to local businesses. While doing
this, the centre will also be an ideal base to provide training services.”
Sunbird S.A. de C.V Managing Director Dr. Francisco José Camargo Santacruz said: “Sunbird is delighted
to be part of TruScreen’s ongoing expansion into the large Mexican market. We are particularly proud to have
played a role in the evolving partnership between TruScreen and Mexpharm. The innovative clinic they have
set up together represents a quantum leap in the quality of women's health in Mexico. And the upside potential
for TruScreen flowing from the partnership is immense, with the female population in this major Central
American country currently around 65 million. It opens the door to a potential new business model, where
TruScreen builds scale and materially grows its Single Use Sensor (SUS) sales into the Mexican market.”
This announcement has been approved by the Board.
-ENDS-
For more information, visit

www.truscreen.com or contact:
Juliet Hull
Chief Executive Officer
juliethull@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Julia Maguire
Investor Relations
julia@thecapitalnetowrk.com.au

+61 2 8999 3699


2
https://hpvcentre.net/statistics/reports/MEX_FS.pdf

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that
has developed an AI-enabled device that can detect precancerous and cancerous cervical changes
in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening
technologies that have only triage/adjunct functionality, the TruScreen device is registered as a
primary screening tool.
TruScreen’s cervical screening technology effectively resolves many of the ongoing issues with
conventional cytology, including failed samples, poor patient follow-up, patient discomfort from
sample collections, and the need for supporting laboratory infrastructure.
The device is CE-marked, meaning it meets EU safety, health and environmental protection standards
required for sale and use throughout Europe. It is also National Medical Products Administration
approved for sale in China.
TruScreen is currently targeting product sales to low and middle-income countries, including China,
Mexico, Vietnam, Russia, Czech Republic, Poland, Serbia, Bosnia, Macedonia, and Saudi Arabia,
where no large-scale cervical cancer screening programs and infrastructure are currently in place. By
doing so, the Company hopes to help improve the health and wellbeing of women worldwide.
To learn more, please visit: www.truscreen.com/